ConcertAI

We’re excited to share a quick recap of our recent presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference, which took place on Wednesday, Sept. 4, 2024. Our CEO, Jeff Elton, took the stage to discuss some thrilling developments at ConcertAI. At the event, we revealed the latest on our CARAai architecture, which now fully supports a new family of Gen AI CoPilots. These innovations build on ConcertAI’s diverse Real-World Data, our advanced Large Language Models, and the latest multi-agent technologies from SymphonyAI. Not to mention, we highlighted the first successful AI workflows from our collaboration with NVIDIA. If you’re interested in more details, you can download the summary of the presentation on our website via the link below: https://hubs.ly/Q02NV81c0 Thank you to everyone who attended the presentation and to Morgan Stanley for hosting us. Your support fuels our commitment to innovate and push the boundaries of what's possible in healthcare. #ConcertAI #HealthcareInnovation #AIinHealthcare #MorganStanleyHealthcareConference #GenAI #ArtificialIntelligence #Partnership #NVIDIA #SymphonyAI

To honor Prostate Cancer Awareness Month, our latest episode of The ConcertAI Podcast features a special session with top urological cancer specialists. Host Jeff Elton welcomes Jennifer R. Rider, ScD, MPH and Kathryn Penney, ScD/PhD to our studio in Harvard Square, Cambridge, MA. Both guests are distinguished cancer epidemiologists who bring a wealth of knowledge and experience in prostate cancer research. In this episode, you will hear about the personal journeys of our guests into the field of cancer research, the significant advancements they have contributed to, and the vital role of genetic studies in improving patient care. The discussion delves into the importance of the Gleason scoring system for determining patient prognosis and explores the integration of AI and digital pathology to enhance diagnosis and treatment strategies. This conversation is essential for anyone interested in the latest in prostate cancer research and the evolving treatment strategies that could redefine patient outcomes. Take a moment to enjoy on your preferred platform: Listen on Apple Podcasts: https://hubs.ly/Q02NPFHx0 Listen on Spotify: https://hubs.ly/Q02NPxR80 #oncology #healthcare #realworlddata #ConcertAIPodcast #podcast #prostatecancer

Get ready for tomorrow's episode on The ConcertAI Podcast where we blend the precision of randomized controlled trials (RCTs) with the practical insights of real-world data. Join our host, Jeff Elton, and ConcertAI leading experts Kathryn Penney and Jennifer R. Rider, ScD, MPH for an engaging discussion on how we’re pushing the boundaries of prostate cancer research. In this soundbite, we explore how ConcertAI is harnessing trial emulation activities to bring the controlled conditions of RCTs into the varied scenarios of real-world studies. Our experts will also discuss the potential of hybrid research models that merge RCT accuracy with real-world flexibility, especially vital in understanding long-term disease states like prostate cancer. Tune in tomorrow for this insightful episode that promises to offer new perspectives on improving patient outcomes through innovative research methodologies. Interested in catching up on all previous podcast episodes? Listen via your preferred platform below: Apple Podcasts: https://hubs.ly/Q02NJLc70 Spotify: https://hubs.ly/Q02NJVV00 #Podcast #ProstateCancer #ProstateCancerAwareness #Research #ClinicalTrials

September is National Prostate Cancer Awareness Month, and we at ConcertAI are doing our part to help raise awareness and find a cure for this all-too-common and all-too-deadly disease. Read the recently released announcement from The White House here: https://hubs.ly/Q02NqWLF0 Toward that end, we're excited to welcome several exciting guests to our upcoming installments of The ConcertAI Podcast later this month. Jennifer R. Rider, ScD, MPH and Kathryn Penney will share their valuable insights on advancing prostate cancer research. Plus, a unique episode featuring special guest senior national correspondent for ABC News, Steve Osunsami, shares his experience and history in his fight against prostate cancer. To learn more about ConcertAI's in-depth prostate cancer research, please visit our Publications library: https://hubs.ly/Q02Nr3XK0. Select "Prostate" under "Show by Cancer Types." Interested in learning more about how ConcertAI's data can help your research study? Leave us a comment below or visit our website to connect with a member of our team. #prostatecancerawarenessmonth #oncology #lifesciences

Join us next week at the 2024 ISPE Annual Meeting in Berlin on August 28th from 8:00 AM – 1:30 PM for a fascinating poster session presented by AbbVie. Dive into the world of "Unlocking Insights: Lessons Learned from the Tokenization of a Psoriasis Trial" By generating unique patient IDs from personal identifying information, tokenization allows for the seamless integration of clinical trial data with real-world data (RWD), enhancing the capture of comorbidities and drug exposure before a trial even begins. In a recent pilot study using ConcertAI’s claims dataset, researchers successfully integrated trial data with RWD through tokenization, providing valuable insights into the baseline characteristics of trial participants. The results showed a high overlap between trial participants and information in open claims, with some discrepancies noted in closed claims. Despite minor discrepancies in baseline comorbidities between the RCT and RWD populations, the integration of data through tokenization has opened up new possibilities for understanding patient profiles and treatment outcomes. These initial findings highlight the potential of tokenization in bridging the gap between clinical trial data and real-world evidence. Read the abstract to learn more: https://hubs.ly/Q02M6b1D0 #Tokenization #HealthcareResearch #DataIntegration #ClinicalTrials #RWD #HIPAACompliant #PatientID #InnovativeResearch #ISPE2024

We are very excited to be presenting an oral presentation next week at the ISPE 2024 Annual meeting. Join us Wednesday, August 28th from 8:30-8:45 AM to hear this presentation live. The objective of this study is to use features from structured and unstructured EHR data to create an Integrated Machine Learning (IML) model to determine the date of metastatic diagnosis of cancer with high accuracy. Natural Language Processing (NLP) is a promising technique to enrich real world data (RWD) by extracting information from unstructured EHR documents. Accurately extracting event dates like dates of metastasis or progression with NLP remains an open research area due to the variety of ways dates are recorded in the real world. Simultaneously, structured data from RWD sources like EHR and Claims provide an array of features informing a patients’ journey. Metastatic diagnosis is a life changing medical event that triggers fundamental changes in patterns of care. We see this reflected in the lab reports, medications, and clinical evidence mentioned in doctor reports. Through extraction of these features, we built an IML model to refine NLP dates from a set of candidates. This work leverages ConcertAI’s industry leading multi-modal oncology data repository, representing more than 8 million patients, covering all 50 states. Combined it enables precision oncology solutioning at scale for problems such as outcome analysis, real world evidence studies, and treatment sequencing optimization. Learn more: https://hubs.ly/Q02LSNr80 Presenting Author: Vivek Vaidya Authors: Vandana Priya, Urvashi (Raheja) Bhattacharyya PhD, Sheenu Chandwani, Herman E. Ray PhD, Srikanth Tankala, Jake Cohen #ISPE2024 #MachineLearning #OncologyResearch #NLP #PrecisionMedicine

Congratulations to Amy Alabaster and Yanina (Yana) Natanzon on their manuscript collaboration with Friends of Cancer Research among other partners in the JCO Clinical Cancer Informatics, American Society of Clinical Oncology (ASCO). This publication demonstrates the feasibility of aligning disparate real-world (rw) data sources to evaluate rw-response to treatment using clinician-documented response in patients with metastatic non-small cell lung cancer (mNSCLC). Alignment of methodologies analyzing real-world data (RWD) is critical for supporting evidence generation using these data RWD to inform oncology drug development and regulatory decision-making. These findings are from the latest pilot project in Friends’ Real-World Evidence Portfolio which establishes methodologies for using real-world data (RWD) to evaluate safety and efficacy of therapies for patients. Read "Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy” here: https://hubs.ly/Q02LJDYb0 #RWEFriends #publication #patients #RWD #EHR

Join the poster session at the 2024 ISPE Annual Meeting in Berlin on August 27th from 8:00 AM – 6:00 PM for a presentation titled: "Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data," presented by AbbVie. Social determinants of health (SDOH) play a crucial role in driving health disparities and impacting clinical research participation among underserved populations. Diversity plans in cancer clinical trials are working to reduce disparities and improve representation through real-world data (RWD). Using ConcertAI’s electronic health record (EHR) database, this study focused on patients with advanced non-small cell lung cancer (aNSCLC) to assess representation based on race, ethnicity, and SDOH. The study found that patients with linked SDOH data were more likely to be non-Hispanic White, had lower levels of education, and lower individual income compared to those without linked SDOH data. These findings highlight the importance of addressing representativeness gaps in clinical trials to ensure equitable access to healthcare. Read the abstract to learn more: https://hubs.ly/Q02LyrkP0 #HealthEquity #ClinicalResearch #SDOH #RepresentationMatters #ISPE2024

We are just one month away from the 2024 ESMO Congress in Barcelona, Spain and ConcertAI will be there! We can't wait to deepen connections and share insights on the complexities and opportunities in medical oncology. Schedule a meeting with us to learn how ConcertAI is using Real World Data to tackle the toughest challenges in drug development. Let's chat and discover how we can work together to drive innovation in Life Sciences. Schedule a time to chat with us: https://hubs.ly/Q02LbqNf0 #ESMO2024 #RealWorldData #MedicalOncology #Innovation #DrugDevelopment

Are you passionate about making a difference in cancer care? ConcertAI is looking for dedicated team members who share our vision of advancing quality, diversity, and efficiency in cancer treatment. We have a range of exciting opportunities available, with perks like work-life flexibility, comprehensive medical benefits, generous PTO and parental leave. If you're ready to join a dynamic team and make a meaningful impact, check out our open positions here: https://hubs.ly/Q02KN07c0 #CancerCare #JoinOurTeam #CareerOpportunities #Hiring